This summary covers recent developments in the health sector, including studies on thyroid medications and asthma drugs, ...
Under Secretary for Health Dr. Shereef Elnahal said Monday the VA needs extra funding to cover the costs of drugs such as ...
10h
The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going ...
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback